Public market insider buying at BriaCell Therapeutics (BCT)

Public market insider buying at BriaCell Therapeutics (T:BCT)

Marc Lustig, a Director and 10% Holder, acquired 55,000 Common Shares on a control or direction basis for registered holder L5 Capital Inc. at a price of $6.463USD on February 2nd, 2022. This represents a $450,602 investment into the company's shares and an account share holdings change of 3.6%.

BriaCell Therapeutics is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

BriaCell Therapeutics Corp. is a clinical stage immunotherapy company. The Company is focused on developing treatments that boost the ability of the body's own cancer-fighting cells to destroy cancerous tumors. Its lead drug candidate, Bria-IMT, is a targeted immunotherapy being developed for the treatment of advanced breast cancer. The Company is focused on conducting Phase I/IIa clinical trial of Bria-IMT in a combination study with immune checkpoint inhibitors such as the Incyte drugs retifanlimab, an anti-PD-1 antibody similar to pembrolizumab, and epacadostat, an orally bioavailable small-molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1). The Company is also focused on development of Bria-OTS, which is an off-the-shelf personalized immunotherapy based on a patient's HLA-type. Its other pre- clinical candidates include Bria-Pros, Bria-Lung, Bria-Mel, Bria-TILsRx and others.